Prana Biotechnology Stock Price, News & Analysis (NASDAQ:PRAN)

$3.19 0.00 (0.00 %)
(As of 12/15/2017 07:07 AM ET)
Previous Close$3.19
Today's Range$3.15 - $3.27
52-Week Range$1.52 - $4.58
Volume16,100 shs
Average Volume143,138 shs
Market Capitalization$28.39 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.11

About Prana Biotechnology (NASDAQ:PRAN)

Prana Biotechnology logoPrana Biotechnology Limited is a development-stage medical biotechnology company. The Company is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's disease, Huntington disease, Parkinson's disease and other neurological disorders. The Company's lead product candidates are PBT2 and PBT434. The Company's lead drug candidate PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. The Company also has advanced a drug candidate for Parkinson's disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. Its other applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease), and a range of orphan neurodegenerative disorders.

Receive PRAN News and Ratings via Email

Sign-up to receive the latest news and ratings for PRAN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PRAN
CUSIPN/A
Phone61-3-9349-4906

Debt

Debt-to-Equity RatioN/A
Current Ratio15.99%
Quick Ratio15.99%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.37 million
Price / Sales11.98
Cash FlowN/A
Price / CashN/A
Book Value$2.01 per share
Price / Book1.59

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees9
Outstanding Shares8,900,000

Prana Biotechnology (NASDAQ:PRAN) Frequently Asked Questions

What is Prana Biotechnology's stock symbol?

Prana Biotechnology trades on the NASDAQ under the ticker symbol "PRAN."

Who are some of Prana Biotechnology's key competitors?

Who are Prana Biotechnology's key executives?

Prana Biotechnology's management team includes the folowing people:

  • Geoffrey Paul Kempler, Executive Chairman of the Board, Chief Executive Officer
  • Kathryn Andrews, Chief Financial Officer
  • Dianne Angus, Chief Operating Officer
  • David Stamler, Chief Medical Officer and Senior Vice President Clinical Development
  • Phillip Hains, Company Secretary
  • Ira Shoulson, Non-Executive Director
  • Lawrence Gozlan, Non-Executive Independent Director
  • Peter Ashley Marks, Non-Executive Independent Director
  • Brian Derek Meltzer, Non-Executive Independent Director
  • George William Mihaly, Non-Executive Independent Director

How do I buy Prana Biotechnology stock?

Shares of Prana Biotechnology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Prana Biotechnology's stock price today?

One share of Prana Biotechnology stock can currently be purchased for approximately $3.19.

How big of a company is Prana Biotechnology?

Prana Biotechnology has a market capitalization of $28.39 million and generates $2.37 million in revenue each year. Prana Biotechnology employs 9 workers across the globe.

How can I contact Prana Biotechnology?

Prana Biotechnology's mailing address is LEVEL 2 369 ROYAL PARADE, PARKVILLE C3, 3052. The biotechnology company can be reached via phone at 61-3-9349-4906 or via email at [email protected]


MarketBeat Community Rating for Prana Biotechnology (PRAN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  55 (Vote Outperform)
Underperform Votes:  72 (Vote Underperform)
Total Votes:  127
MarketBeat's community ratings are surveys of what our community members think about Prana Biotechnology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Prana Biotechnology (NASDAQ:PRAN) Analyst Ratings History


No equities research coverage for this company has been tracked by MarketBeat

Earnings

Earnings History for Prana Biotechnology (NASDAQ:PRAN)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Prana Biotechnology (NASDAQ:PRAN) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Prana Biotechnology (NASDAQ:PRAN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Prana Biotechnology (NASDAQ PRAN)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Prana Biotechnology (NASDAQ PRAN) News Headlines

Source:
DateHeadline
Prana Biotechnology Ltd (PRAN) Upgraded by ValuEngine to SellPrana Biotechnology Ltd (PRAN) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - October 22 at 1:34 PM
Senestech (SNES) and Prana Biotechnology (PRAN) Head to Head ReviewSenestech (SNES) and Prana Biotechnology (PRAN) Head to Head Review
www.americanbankingnews.com - October 15 at 10:22 AM
BRIEF-Prana Biotechnology files for mixed shelf of upto $50 mlnBRIEF-Prana Biotechnology files for mixed shelf of upto $50 mln
www.reuters.com - October 12 at 8:28 AM
Comparing Nektar Therapeutics (NKTR) & Prana Biotechnology (PRAN)Comparing Nektar Therapeutics (NKTR) & Prana Biotechnology (PRAN)
www.americanbankingnews.com - October 11 at 4:32 AM
The List of Failed Alzheimer’s Drug Treatments Keeps GrowingThe List of Failed Alzheimer’s Drug Treatments Keeps Growing
247wallst.com - September 26 at 7:11 PM
Prana Commences Research Collaboration with Takeda for the Treatment of Parkinsons Disease Gastrointestinal NeuropathologyPrana Commences Research Collaboration with Takeda for the Treatment of Parkinson's Disease Gastrointestinal Neuropathology
finance.yahoo.com - July 19 at 5:05 AM
Head to Head Analysis: Prana Biotechnology (NASDAQ:PRAN) & Threshold Pharmaceuticals (THLD)Head to Head Analysis: Prana Biotechnology (NASDAQ:PRAN) & Threshold Pharmaceuticals (THLD)
www.americanbankingnews.com - July 12 at 2:08 PM
UPDATE: Prana Biotech (NASDAQ: PRAN) Announces PBT434 Lowers Alpha-Synuclein & Prevents NeurodegenerationUPDATE: Prana Biotech (NASDAQ: PRAN) Announces PBT434 Lowers Alpha-Synuclein & Prevents Neurodegeneration
www.streetinsider.com - July 7 at 8:15 AM
Todays Research Reports on Stocks to Watch: Opexa Therapeutics and Prana BiotechnologyToday's Research Reports on Stocks to Watch: Opexa Therapeutics and Prana Biotechnology
finance.yahoo.com - July 5 at 9:45 AM
Pranas PBT434 Lowers Alpha-Synuclein and Prevents NeurodegenerationPrana's PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration
finance.yahoo.com - July 5 at 9:45 AM
BUZZ-U.S. STOCKS ON THE MOVE-ConocoPhillips, Cenovus, Lululemon, Prana Biotech, SAIC - NasdaqBUZZ-U.S. STOCKS ON THE MOVE-ConocoPhillips, Cenovus, Lululemon, Prana Biotech, SAIC - Nasdaq
www.nasdaq.com - March 31 at 8:33 AM
Prana Biotechnology Ltd (PRAN)Prana Biotechnology Ltd (PRAN)
seekingalpha.com - March 30 at 7:36 PM
Prana: Expect Success In Massive Binary EventPrana: Expect Success In Massive Binary Event
seekingalpha.com - March 26 at 8:03 AM

SEC Filings

Prana Biotechnology (NASDAQ:PRAN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Prana Biotechnology (NASDAQ:PRAN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Prana Biotechnology (NASDAQ PRAN) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.